Apogee Therapeutics Inc (APGE) Stock Price, Quote & News

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

LadsAndGents Sep. 12 at 2:54 PM

$APGE breaking into 39 would be key.. then 43

0 · Reply

LadsAndGents Sep. 6 at 1:36 AM

$APGE why this always falls after hours ?

0 · Reply

CH_Expat Aug. 29 at 5:51 AM

$APGE $BHVN are the only not-trash bios left with an undervaluation apart from CRNX und IDYA. Not easy to deploy what to do with the cash. Ideas? Cc: @WSRX @RonIsWrong @CDMO @Pika_Capital

4 · Reply

MedicalDoctorInvestor Aug. 28 at 7:49 PM

$APGE wow, a dumpster fire today

0 · Reply

MedicalDoctorInvestor Aug. 28 at 5:05 PM

$APGE red once again

0 · Reply

JarvisFlow Aug. 28 at 3:54 PM

B of A Securities updates rating for Apogee Therapeutics ( $APGE ) to Buy, target set at 78 → 87.

0 · Reply

Quantumup Aug. 28 at 11:00 AM

BofA⬆️ $APGE PT to $87 from $78 and reiterated at a Buy rating. $REGN $SNY $CRVS LLY $NKTR BofA said:

0 · Reply

TriggerRaider Aug. 23 at 5:46 AM

$APGE Apogee Therapeutics is a clinical stage immunology company with promising early data

0 · Reply

idk_idk Aug. 19 at 1:47 PM

$APGE Up or down from here?

0 · Reply

d_risk Aug. 12 at 1:03 AM

$APGE - Apogee Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors APGE’s latest 10-Q risk factors streamline prior disclosures, add new warnings on limited operating history, funding needs, dual class stock, and forum selection, expand on FDA delays, compliance, and litigation risks, and remove several prior concerns including insider control, anti-takeover, and dividend policies. #Biotechnology #CorporateGovernance #FDADelays #FundingNeeds #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/APGE/10-Q/2025-08-11

0 · Reply